Table 1. Characteristics of studies.

Authors and year of publication	Total population	Age (years)	Intervention drug	Intervention duration	Instrument
Hollway et al.¹⁰, 2017	128	5–14	Atomoxetine	10 weeks	Children’s Sleep Habits Questionnaire
Rugino¹¹, 2014	29	6–12	Guanfacine extended release (GXR)	5 weeks	Polysomnography and Children’s Sleep Habits Questionnaire
Ricketts et al.¹², 2018	576	7–9	Methylphenidate	14 months	Achenbach Child Behavior Checklist 6-18
Goldman et al.¹⁸, 2018	342	6–12	Dasotraline	6 weeks	Children’s Sleep Habits Questionnaire
Owens et al.¹³, 2016	256	Study 1: 6–12 Study 2: 6–18	Methylphenidate HCl extended-release capsules	16 weeks	Children’s or Adolescent Sleep Habits Questionnaire
Becker et al.¹⁷, 2016	163	7–11	Methylphenidate	4 weeks	Pittsburgh Side Effects Rating Scale
Stein et al.¹⁶, 2015	230	Uninformed	Methylphenidate and atomoxetine	3–7 weeks	A sleep assessment scale validated and completed by parents
Lyon et al.¹⁹, 2011	93	8–12	L-Theanine chewable tablets	6 weeks	Pediatric Sleep Questionnaire and actigraphy
Solleveld et al.¹⁴, 2020	50	10–12	Immediate-release methylphenidate	16 weeks	Actigraphy, Holland Sleep Disorder Questionnaire; Epworth Sleepiness Scale, and Evaluation List Insomnia Therapy
Ashkenasi¹⁵, 2011	26	6–12	Transdermal methylphenidate	4 weeks	Daily updated sleep diary
Giblin and Strobel²⁰, 2011	24	6–12	LDX administration	3 weeks	Polysomnography, actigraphy, and CSHQ